A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Clinical trial NCT05394350 · TERMINATED

Trial details

NCT number: NCT05394350
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2022-07-07
Primary completion: 2023-09-07
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.